Mouhieddine TH, Van Oekelen O, Melnekoff DT, et al. Sequencing T-Cell Redirection Therapies Leads to Deep and Durable Responses in Relapsed/Refractory Myeloma Patients. Blood Advances. 2022; (doi: 10.1182/bloodadvances.2022007923).
Sequential T-cell redirection therapy can induce deep and durable responses in relapsed/refractory multiple myeloma patients who relapse following bispecific antibody (BiAb) treatment, new research shows. For the study, researchers identified from a BiAb trial 58 patients (median age 67 years) who were progressing. More than three-quarters of the patients (78%) had high-risk cytogenetics, with 89% triple-class refractory and 44% penta-drug refractory. Patients were monitored for a median of 30.5 months after the BiAb trial and underwent an average of two additional salvage therapies. T-cell redirection was the most frequent first salvage with 19 patients (10 BiAb and nine CAR-T), and it was administered as second savage therapy to 10 patients. T-cell redirection therapy was linked to a median 28.9-month progression-free survival (PFS) to first salvage therapy and a 30.9-month PFS to second salvage therapy, with an overall survival rate of 62% at 2 years.
Read More